<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4474"><DrugName>xaliproden</DrugName><DrugNamesKey><Name id="42767520">Xaprila</Name><Name id="43073331">xaliproden</Name></DrugNamesKey><DrugSynonyms><Name><Value>SR-57746A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Xaprila</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>SR-57746</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SS-57746</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>xaliproden hydrochloride</Value></Name><Name><Value>xaliproden</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>xaliprodene</Value></Name><Name><Value>90494-79-4</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>135354-02-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26494">Sanofi-Synthelabo</CompanyOriginator><CompaniesSecondary><Company id="1009547">Sanofi SA</Company><Company id="24951">Nippon Sanofi</Company><Company id="26494">Sanofi-Synthelabo</Company><Company id="26658">Sanofi Recherche SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4474" type="Drug"><TargetEntity id="162594" type="siDrug">Xaliproden hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="24951" type="Company"><TargetEntity id="5035523740" type="organizationId">Nippon Sanofi Co Ltd</TargetEntity></SourceEntity><SourceEntity id="26494" type="Company"><TargetEntity id="5000326934" type="organizationId">Sanofi Synthelabo Caraibes SARL</TargetEntity></SourceEntity><SourceEntity id="26658" type="Company"><TargetEntity id="5035524034" type="organizationId">Sanofi Recherche SA</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="212" type="ciIndication"><TargetEntity id="G12.2" type="ICD10"></TargetEntity><TargetEntity id="10028003" type="MEDDRA"></TargetEntity><TargetEntity id="D016472" type="MeSH"></TargetEntity><TargetEntity id="1290" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"></TargetEntity><TargetEntity id="10028245" type="MEDDRA"></TargetEntity><TargetEntity id="D009103" type="MeSH"></TargetEntity><TargetEntity id="-1241225595" type="omicsDisease"></TargetEntity><TargetEntity id="112" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="233" type="ciIndication"><TargetEntity id="10053643" type="MEDDRA"></TargetEntity><TargetEntity id="D019636" type="MeSH"></TargetEntity><TargetEntity id="-1502359765" type="omicsDisease"></TargetEntity><TargetEntity id="160" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="678" type="ciIndication"><TargetEntity id="1308" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1590" type="Action"><TargetEntity id="1063" type="Mechanism">Apoptosis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="6" type="Action"><TargetEntity id="220" type="Mechanism">5-HT1A Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00011" type="ciTarget"><TargetEntity id="100215858133503" type="siTarget">5-hydroxytryptamine receptor 1A</TargetEntity><TargetEntity id="4469" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="PR">Pre-registration</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1089">Neurotoxicity drug-induced</Indication><Indication id="14">Alzheimers disease</Indication><Indication id="212">Motor neurone disease</Indication><Indication id="213">Multiple sclerosis</Indication><Indication id="233">Neurodegenerative disease</Indication><Indication id="678">Neuropathy</Indication></IndicationsSecondary><ActionsPrimary><Action id="6">5-HT 1a receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1590">Apoptosis inhibitor</Action><Action id="1615">Neuroprotectant</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-02T17:36:43.000Z</LastModificationDate><ChangeDateLast>2017-02-13T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi-aventis&lt;/ulink&gt; (formerly &lt;ulink linkID="26494" linkType="Company"&gt;Sanofi-Synthelabo&lt;/ulink&gt;) was developing xaliproden (xaliprodene, SR-57746, Xaprila), an oral, non-peptide, 5-HT1A agonist that stimulates endogenous neurotrophin synthesis and prevents p75-mediated apoptosis, as an orally available neurotropic for the potential treatment of  neuropathies associated with cancer chemotherapy, especially oxaliplatin [&lt;ulink linkID="295681" linkType="Reference"&gt;295681&lt;/ulink&gt;], [&lt;ulink linkID="328910" linkType="Reference"&gt;328910&lt;/ulink&gt;], [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;].  In March 2006, the drug was listed as phase III for chemotherapy-induced neuropathy [&lt;ulink linkID="676791" linkType="Reference"&gt;676791&lt;/ulink&gt;].   In February 2008, filing was expected in 2009 [&lt;ulink linkID="875929" linkType="Reference"&gt;875929&lt;/ulink&gt;]. By July 2009, development for chemotherapy-induced neuropathy had been discontinued, after a phase III study failed to reach its primary endpoint [&lt;ulink linkID="1029237" linkType="Reference"&gt;1029237&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Xaliproden was under development for Alzheimer's disease (AD). By September 2003, xaliproden had entered phase III trials for AD [&lt;ulink linkID="503537" linkType="Reference"&gt;503537&lt;/ulink&gt;], [&lt;ulink linkID="505808" linkType="Reference"&gt;505808&lt;/ulink&gt;], [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;]; these trials were ongoing in February 2006 [&lt;ulink linkID="652672" linkType="Reference"&gt;652672&lt;/ulink&gt;]. However, xaliproden did not meet its cognition endpoints in these studies and, by September 2007, development was terminated for this indication [&lt;ulink linkID="830743" linkType="Reference"&gt;830743&lt;/ulink&gt;], [&lt;ulink linkID="830785" linkType="Reference"&gt;830785&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Xaliproden was under development for multiple sclerosis (MS). In August 2005, the drug was in phase IIa studies for MS [&lt;ulink linkID="620762" linkType="Reference"&gt;620762&lt;/ulink&gt;]. However, this indication was not mentioned on sanofi-aventis' February 2006 pipeline [&lt;ulink linkID="652672" linkType="Reference"&gt;652672&lt;/ulink&gt;]. It has also previously been developed as an anxiolytic [&lt;ulink linkID="295681" linkType="Reference"&gt;295681&lt;/ulink&gt;] and for amyotrophic lateral sclerosis (ALS) [&lt;ulink linkID="295681" linkType="Reference"&gt;295681&lt;/ulink&gt;], [&lt;ulink linkID="328910" linkType="Reference"&gt;328910&lt;/ulink&gt;]. Orphan drug status for this indication was granted in Europe in January 2001, with an NDA file made in June 2001 [&lt;ulink linkID="432268" linkType="Reference"&gt;432268&lt;/ulink&gt;], [&lt;ulink linkID="416909" linkType="Reference"&gt;416909&lt;/ulink&gt;], [&lt;ulink linkID="440812" linkType="Reference"&gt;440812&lt;/ulink&gt;]. However, by September 2002, this filing had been withdrawn [&lt;ulink linkID="463211" linkType="Reference"&gt;463211&lt;/ulink&gt;], and the indication was not listed on the company's pipeline released in February 2003 [&lt;ulink linkID="479170" linkType="Reference"&gt;479170&lt;/ulink&gt;], [&lt;ulink linkID="483460" linkType="Reference"&gt;483460&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;TheUS&lt;/subtitle&gt;In September 2000, filing for ALS in the US was expected in the first quarter of 2001 [&lt;ulink linkID="382998" linkType="Reference"&gt;382998&lt;/ulink&gt;], [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="387919" linkType="Reference"&gt;387919&lt;/ulink&gt;], which was later revised to the second quarter of 2001 [&lt;ulink linkID="377124" linkType="Reference"&gt;377124&lt;/ulink&gt;], [&lt;ulink linkID="399945" linkType="Reference"&gt;399945&lt;/ulink&gt;]. Orphan Drug status had also been expected in the US for this indication [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="382998" linkType="Reference"&gt;382998&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;The EU&lt;/subtitle&gt;In August 2000, Xaliproden was submitted for Orphan Drug status in Europe for the treatment of ALS [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;]; the status was granted to the company in January 2001 [&lt;ulink linkID="432268" linkType="Reference"&gt;432268&lt;/ulink&gt;]. In September 2000, filing for ALS in Europe was expected in the first quarter of 2001 [&lt;ulink linkID="382998" linkType="Reference"&gt;382998&lt;/ulink&gt;], [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="387919" linkType="Reference"&gt;387919&lt;/ulink&gt;], which was later revised to the second quarter of 2001 [&lt;ulink linkID="377124" linkType="Reference"&gt;377124&lt;/ulink&gt;], [&lt;ulink linkID="399945" linkType="Reference"&gt;399945&lt;/ulink&gt;]. In June 2001, an NDA was filed [&lt;ulink linkID="416909" linkType="Reference"&gt;416909&lt;/ulink&gt;], [&lt;ulink linkID="440812" linkType="Reference"&gt;440812&lt;/ulink&gt;], however, the filing had been withdrawn by September 2002 [&lt;ulink linkID="463211" linkType="Reference"&gt;463211&lt;/ulink&gt;]. This indication was not listed on the company's pipeline released in February 2003 [&lt;ulink linkID="479170" linkType="Reference"&gt;479170&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;NDA submission had been expected for ALS in 2001 in Japan [&lt;ulink linkID="377124" linkType="Reference"&gt;377124&lt;/ulink&gt;], [&lt;ulink linkID="399945" linkType="Reference"&gt;399945&lt;/ulink&gt;]. Orphan Drug status has been received in Japan [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="382998" linkType="Reference"&gt;382998&lt;/ulink&gt;], but in February 2004, this was revoked [&lt;ulink linkID="525068" linkType="Reference"&gt;525068&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Chemotherapy-associated neuropathy&lt;/subtitle&gt;By February 2007, an exploratory study was underway. Patients with colorectal cancer (expected n =154) who had completed a course of oxaliplatin chemotherapy were to receive xaliproden 1 mg/day or placebo for up to 6 months after the last oxaliplatin infusion until neuropathy was resolved [&lt;ulink linkID="765668" linkType="Reference"&gt;765668&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2006, a second Xenox study was underway [&lt;ulink linkID="652672" linkType="Reference"&gt;652672&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2005, a randomized, double-blind, placebo-controlled phase  III trial (EFC5505, NCT00305188) was initiated in subjects (expected n = 900) with metastatic colorectal cancer undergoing FOLFOX treatment in the US, South America, Europe,  Canada and Australia. The subjects were to receive placebo or xaliproden. The primary endpoint was risk of peripheral sensory neuropathy (PSN) between the two groups and the secondary endpoints included response to chemotherapy. The study was still recruiting in October 2006 [&lt;ulink linkID="755722" linkType="Reference"&gt;755722&lt;/ulink&gt;]. In February 2007, results were expected at the end of 2008 [&lt;ulink linkID="765668" linkType="Reference"&gt;765668&lt;/ulink&gt;]. In July 2009, sanofi-aventis reported that a phase III study, presumed to be this one, had not reached its primary endpoint [&lt;ulink linkID="1029237" linkType="Reference"&gt;1029237&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005, results were released from the phase III Xenox study in 649 metastatic colorectal cancer patients treated with FOLFOX4. The relative risk of oxaliplatin-associated grade 3 peripheral sensory neuropathy was reduced by 39% by treatment with xaliproden 1 mg qd. The response rate to chemotherapy was not affected by xaliproden treatment and no additional adverse events were observed [&lt;ulink linkID="620356" linkType="Reference"&gt;620356&lt;/ulink&gt;], [&lt;ulink linkID="620762" linkType="Reference"&gt;620762&lt;/ulink&gt;]. Similar data were reported in January 2006 [&lt;ulink linkID="648496" linkType="Reference"&gt;648496&lt;/ulink&gt;], [&lt;ulink linkID="649031" linkType="Reference"&gt;649031&lt;/ulink&gt;] and in June 2006 at the 42nd ASCO meeting in Atlanta, GA. In the test group of 325 patients, the response rate was 44.9% (placebo group was 42.6%). Other factors compared showed largely similar comparative values; however, this trend was not shown in the occurrence of pulmonary embolism. The occurrence of this adverse event was reduced by 37% in the test group compared to the control group, effectively reducing grade 3/4 PSN to grade 2 [&lt;ulink linkID="671501" linkType="Reference"&gt;671501&lt;/ulink&gt;], [&lt;ulink linkID="671646" linkType="Reference"&gt;671646&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Alzheimer's disease&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2005, a placebo-controlled, randomized, double-blind phase III trial (NCT00103649; EFC2946; SR57746) was initiated in subjects with mild-to-moderate AD in the US and Canada. The subjects were to receive xaliproden once daily. The endpoints were safety and efficacy. The study was completed in October 2006 [&lt;ulink linkID="816526" linkType="Reference"&gt;816526&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2003, two double-blind phase III trials, to compare the efficacy of xaliproden (0.5 mg/day po) against placebo in 2400 patients with AD, had begun. The primary efficacy phase was expected to complete in 18 months [&lt;ulink linkID="503537" linkType="Reference"&gt;503537&lt;/ulink&gt;]. In February 2007, the last patient visit was expected in the first half of 2007 [&lt;ulink linkID="765666" linkType="Reference"&gt;765666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;Phase II studies have demonstrated that xaliproden slows down the progression of AD and may even help restore cerebral function. At the end of 1997, &lt;ulink linkID="26495" linkType="Company"&gt;Sanofi&lt;/ulink&gt; was negotiating with the regulatory authorities in the design of phase III trials to monitor reversal of AD. At this time, the company expected that recruitment would commence no earlier than the second half of 1998, that the trial would last for about 18 months and that the drug would be filed in 2001 for this indication [&lt;ulink linkID="270168" linkType="Reference"&gt;270168&lt;/ulink&gt;], [&lt;ulink linkID="270242" linkType="Reference"&gt;270242&lt;/ulink&gt;]. However, in February 2000, the compound was still in phase IIb trials for AD [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="358849" linkType="Reference"&gt;358849&lt;/ulink&gt;], [&lt;ulink linkID="440812" linkType="Reference"&gt;440812&lt;/ulink&gt;]. By the end of 2002, the phase IIb AD trials had been completed and a phase III international program for this indication was anticipated to begin in 2003 [&lt;ulink linkID="487359" linkType="Reference"&gt;487359&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Amyotrophic lateral sclerosis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By February 2000, it had completed phase III pivotal trials for ALS [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="358849" linkType="Reference"&gt;358849&lt;/ulink&gt;]. In August 2000, xaliproden had not progressed beyond phase III for ALS and phase II trials for AD [&lt;ulink linkID="380502" linkType="Reference"&gt;380502&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Two placebo-controlled phase III ALS trials, involving administration of 1 or 2 mg daily doses of xaliproden for 18 months, were initiated in May 1997. One of the trials (EFC 923) also involved administration of 100 mg &lt;ulink linkID="5859" linkType="Drug"&gt;riluzole&lt;/ulink&gt; (qv). At this time, filing for ALS was expected in 1999 [&lt;ulink linkID="270242" linkType="Reference"&gt;270242&lt;/ulink&gt;]. By December 1998, over 2000 patients had been enrolled and the trial results were expected in 2000 [&lt;ulink linkID="330073" linkType="Reference"&gt;330073&lt;/ulink&gt;]. By February 2000, both trials had been completed and the results of the trials were being analyzed [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="358849" linkType="Reference"&gt;358849&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Preliminary results of two pivotal trials of xaliproden in ALS patients treated with xaliproden and with the xaliproden/&lt;ulink linkID="5859" linkType="Drug"&gt;riluzole&lt;/ulink&gt; combination have shown that the compound is well tolerated. Xaliproden had a positive effect on pulmonary function, resulting in favorable trends in survival, as well as a positive effect on parameters related to the rate of progression of the disease. In September 2000, additional in-depth analysis was in progress [&lt;ulink linkID="381192" linkType="Reference"&gt;381192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In phase II trials in patients with ALS, xaliproden has been shown to slow the rate of decline of functional capacities [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a placebo-controlled, phase I/II trial in 32 patients with neurodegenerative diseases, patients exhibited a positive trend in muscle strength and a reduction in the rate of decline of pulmonary function [&lt;ulink linkID="269672" linkType="Reference"&gt;269672&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2007, preclinical data on xaliproden were presented at the 37th SFN meeting in San Diego, CA. The compound exhibited pKi values of 8 and 9 at rat and human 5-HT1A receptors, compared to 9.2 and 9.5 for &lt;ulink linkID="31394" linkType="Drug"&gt;SSR-181507&lt;/ulink&gt;, and 9 and 9.3 for (+/-)-8-OH-DPAT, respectively. GTPgammaS incorportation in hippocampal membranes was stimulated with a pEC50 value of 7.6 for xaliproden, compared to 7 for the other compounds. In vivo models showed that doses from 0.63 to 10 mg/kg ip resulted in significant reductions of formalin-induced paw elevation and licking in both acute and late phases, and the effects could be blocked by pretreatment with WAY-100635 [&lt;ulink linkID="847523" linkType="Reference"&gt;847523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, preclinical data were presented on xaliproden at the 97th AACR meeting in Washington DC. In vitro xaliproden was evaluated in combination with &lt;ulink linkID="3792" linkType="Drug"&gt;oxaliplatin&lt;/ulink&gt;  against CoLo 205, LoVo and HCT116 human colon carcinoma cell lines. Xaliproden alone had no effect on cell proliferation and, at a dose of 10 microM, had no effect on oxaliplatin antiproliferative activity with IC50 values of 2.26, 0.79 and 1.44 microM against CoLo, LoVo and HCT116 respectively, compared to IC50 values for oxaliplatin alone of 1.6, 0.39 and 0.54 microM, respectively, for the same cell lines. In vivo in colon C51 adenocarcinoma xenografts in BALB/c mice, oxaliplatin was administered, alone or in combination, iv on 14 and 18 days post tumor implantation at 11.7, 7 and 4.2 mg/kg/injection. Xaliproden was administered daily at 1 mg/kg/day po 14 days post tumor implantation, both alone and in combination with oxaliplatin. Single-agent xaliproden (total dose = 10 mg/kg) induced a maximal body weight loss of 15.2%. The combination was well tolerated, with the highest non-toxic combination producing 13% body weight loss, occurring 1 day post last oxaliplatin treatment.The highest nontoxic combination was oxaliplatin at 7 mg/kg/injection with xaliproden. It was found highly active with six of six complete responses. At the lower dose of 4.2 mg/kg/injection of oxaliplatin, activity was also maintained with six of six showing complete response [&lt;ulink linkID="657251" linkType="Reference"&gt;657251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005, preclinical results were disclosed, showing that treatment with 3 or 10 mg/kg xaliproden protected oxaliplatin-induced cold allodynia in rats. Xaliproden treatment had no effect on oxaliplatin's efficacy in mice bearing colon adenocarcinomas. Results were also presented from a preclinical study in rats lesioned using vincristine, a model of AD. Xaliproden treatment protected choline acetyltransferase activity and social memory as effectively as NGF  [&lt;ulink linkID="620356" linkType="Reference"&gt;620356&lt;/ulink&gt;], [&lt;ulink linkID="620762" linkType="Reference"&gt;620762&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In glioma cell cultures, xaliproden enhances the effects of NGF on cell survival and neurite outgrowth and stimulates the production of NGF mRNA. Xaliproden administered to marmosets reduced cholinergic lesions induced by intraseptal vincristine and was active after acute, or repeated, oral administration [&lt;ulink linkID="183260" linkType="Reference"&gt;183260&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, preclinical data on xaliproden were presented at the 30th Neuroscience meeting in New Orleans, LA, demonstrating that the neuroprotective mechanism of action of xaliproden involves stimulation of an increase in the levels of either one or both of NGF and BDNF [&lt;ulink linkID="390308" linkType="Reference"&gt;390308&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;As of February 2003, insufficient additional data were available on which to base an updated evaluation of this drug.&lt;/para&gt;&lt;para&gt;Report written by a senior scientist at an international pharmaceutical company.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;26 July 2000&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4474"&gt;Xaliprodene&lt;/ulink&gt; (SR-57746A) is under development by &lt;ulink linkType="Company" linkID="26494"&gt;Sanofi-Synthelabo&lt;/ulink&gt; (previously &lt;ulink linkType="Company" linkID="26495"&gt;Sanofi&lt;/ulink&gt;) as an orally active neurotrophic-like agent for the potential treatment of Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) [&lt;ulink linkType="reference" linkID="295681"&gt;295681&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="328910"&gt;328910&lt;/ulink&gt;]. It has also previously been developed as an anxiolytic [&lt;ulink linkType="reference" linkID="295681"&gt;295681&lt;/ulink&gt;]. Considerable preclinical data have demonstrated that the compound has neurotrophic-like activity, both in vitro and in vivo and may exert at least some of its effects by stimulation of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or neurotrophin (NT)-3 expression. It has completed phase III pivotal trials for ALS and is in phase IIb trials for AD [&lt;ulink linkType="reference" linkID="359231"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="358849"&gt;358849&lt;/ulink&gt;]. In February 2000, &lt;ulink linkType="Company" linkID="26494"&gt;Sanofi-Synthelabo&lt;/ulink&gt; is expected to file for registration for ALS in Europe and the US in the fourth quarter of 2000 and in Japan, where the compound has Orphan Drug status, in 2001 [&lt;ulink linkType="reference" linkID="359231"&gt;359231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;No data are available on the synthesis of &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; (1-(2-napthylethyl)-4-(3-trifluoromethyl)-1,2,3,6-tetrahydropyridine).&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4474"&gt;Xaliprodene&lt;/ulink&gt; has neuroprotective and neuroregenerative properties in a number of in vivo and in vitro assays in which neuronal survival or differentiation is compromised. Originally developed as an anxiolytic/antidepressant because of its high affinity and selectivity for the 5-HT1A receptor, its mechanism of action is essentially unknown, although it acts functionally as a growth factor mimetic.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;In vitro&lt;/subtitle&gt;In experiments performed in vitro, &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; shows clear growth factor-like properties. Thus, it increases the phenotypic survival of embryonic mouse motor neurons to the same extent as BDNF and increases the outgrowth and number of their neurites [&lt;ulink linkType="reference" linkID="367217"&gt;367217&lt;/ulink&gt;]. Rapid neurite retraction and transient rounding of serum-starved NG108-15 and PC12 cells by lysophosphatidic acid (LPA) is retarded and reduced by pre-incubation of the cells. The compound also antagonizes the redistribution of filamentous actin by LPA in both cell types [&lt;ulink linkType="reference" linkID="283322"&gt;283322&lt;/ulink&gt;]. Furthermore, a significant increase in the percentage of PC12 cells bearing neurite-like processes was obtained in cells treated with &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; and NGF compared to those treated with NGF alone. &lt;ulink linkType="Drug" linkID="4474"&gt;Xaliprodene&lt;/ulink&gt; alone, however, had no effect on morphogenesis or on survival of cells in serum-free medium. In contrast, &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; induced a 'priming' effect on PC12 cells for neurite outgrowth within 6 h of addition of the protein tyrosine kinase inhibitor, genistein. An increase in b-actinin content resulted from treatment with &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt;. Expression of NGF-mediated acetylcholinesterase and ChAT was enhanced within 5 days by &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt;. The molecule also induced rapid F-actin redistribution. Within 2 min of incubation, outgrowth of F-actin-containing filopodia was clearly visible at the cell periphery, as previously shown with NGF [&lt;ulink linkType="reference" linkID="184449"&gt;184449&lt;/ulink&gt;]. In contrast to NGF, NT-3 does not increase the differentiation of PC12 cells. However, when incubated with &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt;, NT-3 significantly increased outgrowth while combination with BDNF or NT-4 was without effect [&lt;ulink linkType="reference" linkID="285356"&gt;285356&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The mechanisms by which &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; exerts its neurotrophic-like effects has been evaluated in primary cultures of rat cortical astrocytes. The compound induces a concentration and time-dependent increase in NGF mRNA with lesser, but still significant effects on BDNF mRNA and no effect on F-actin mRNA [&lt;ulink linkType="reference" linkID="367225"&gt;367225&lt;/ulink&gt;]. However, the part played by its ability to interact with the 5-HT1A receptor in these effects is much less clear.&lt;/para&gt;&lt;para&gt;In a variety of in vitro binding studies, &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; has been found to bind to 5-HT1A receptors with Ki values of between 1 and 2 nM. Little affinity is evident at other 5-HT receptor subtypes, or at other receptors, except sigma receptors [&lt;ulink linkType="reference" linkID="178001"&gt;178001&lt;/ulink&gt;]. The in vivo occupancy of 5-HT1A receptors by injected &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; has been determined, and a dose of 11.1 mg/kg po is able to displace 50% of the binding of previously injected 3H-8-OH-DPAT. This occupation of 5-HT1A receptors would appear to be long lasting, with an effect still evident 24 h after systemic administration. The inhibition of forskolin-stimulated adenylate cyclase in rat hippocampal homogenates by &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; suggests that it acts as a full agonist, resembling the reference full agonist 8-OH-DPAT. Consistent with these properties, &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; reduced 5-HT turnover in the brains of rats via an action on cell body 5-HT1A receptors in the raphe nuclei and, after iv injection, inhibited the firing of raphe neurons. These data are consistent with the properties of a 5-HT1A receptor agonist [&lt;ulink linkType="reference" linkID="178001"&gt;178001&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;5-HT1A ligands modulate cholinergic function both in vivo and in vitro in a variety of preparations. For example, in vitro treatment of primary cultures of fetal rat septal neurons with 8-OH-DPAT, &lt;ulink linkType="Drug" linkID="3399"&gt;ipsapirone&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14455"&gt;Bayer AG&lt;/ulink&gt;), gepirone (&lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb Co&lt;/ulink&gt;) or &lt;ulink linkType="Drug" linkID="44364"&gt;buspirone&lt;/ulink&gt; increases ChAT activity after 6 to 7 days in culture [&lt;ulink linkType="reference" linkID="178007"&gt;178007&lt;/ulink&gt;]. This effect can be prevented by pretreatment with the 5-HT1A antagonist (+)-&lt;ulink linkType="Drug" linkID="4883"&gt;WAY-100135&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14112"&gt;Wyeth&lt;/ulink&gt; Ayerst Pharmaceuticals Inc), suggesting that the effect is modulated by 5-HT1A receptors. However, the ability of 5-HT1A receptor agonists to stimulate growth factor-like activity has been questioned since the effects of &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; on NGF synthesis were not mimicked by 8-OH-DPAT [&lt;ulink linkType="reference" linkID="367225"&gt;367225&lt;/ulink&gt;]. Nevertheless, it is interesting that a structurally disimilar 5-HT1A receptor agonist, &lt;ulink linkType="Drug" linkID="12980"&gt;repinotan&lt;/ulink&gt; (BAY-X-3702; &lt;ulink linkType="Company" linkID="14455"&gt;Bayer AG&lt;/ulink&gt;) is also in development as a neuroprotective and anti-apoptotic agent and many of the neuroprotective effects of this compound can be blocked by the 5-HT1A receptor antagonist, &lt;ulink linkType="Drug" linkID="8350"&gt;WAY-100635&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14112"&gt;American Home Products Corp&lt;/ulink&gt;) [&lt;ulink linkType="reference" linkID="259298"&gt;259298&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="375604"&gt;375604&lt;/ulink&gt;]. Thus, the mechanism of action of &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; may not be independent of an agonist action at 5-HT1A receptors.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;In vivo&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4474"&gt;Xaliprodene&lt;/ulink&gt; shows neuroprotective effects in rats exposed to transient global cerebral ischemia induced by four-vessel occlusion [&lt;ulink linkType="reference" linkID="135343"&gt;135343&lt;/ulink&gt;]. When given orally at 2.5 to 10 mg/kg daily for 10 days, scores for ischemia-induced neuronal damage were reduced by 30 to 40% by &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; in hippocampal CA1, CA2 and CA3 regions and in dorsal striatum. In the sciatic nerve crush model, sensorimotor function improved more rapidly in &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt;-treated rats (10 mg/kg), an effect that correlated with an increase in length of regenerated nerve, least as measured functionally by the pinch test [&lt;ulink linkType="reference" linkID="135343"&gt;135343&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;After post-natal unilateral section of rat sciatic nerve, only about 50% of motor neurons survive in the fourth lumbar segment of the spinal cord. However, with 14 days of consecutive treatment with &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt;, the number of surviving neurons increased significantly, although there was no effect on motor neuron diameter. The results suggest that &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; is a survival factor for motor neurons in vivo [&lt;ulink linkType="reference" linkID="375530"&gt;375530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a demonstration of its ability to counteract drug-induced neurotoxicity, vincristine-induced reductions in choline acetyltransferase (ChAT) activity in the septum and hippocampus were reduced dose-dependently by &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; in both rat and marmoset in parallel with reverses in vincristine-induced changes in behavior (exploratory activity and short-term social memory, respectively) [&lt;ulink linkType="reference" linkID="135343"&gt;135343&lt;/ulink&gt;]. Similarly, the injection of beta-amyloid (Abeta)1-40 or Abeta25-35, but not Abeta1-41 or scrambled peptide into the rat medial septum induced a deficit in retention of social short-term memory that was reversed by daily treatment for 21 days with &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; (10 mg/kg po) [&lt;ulink linkType="reference" linkID="198878"&gt;198878&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="4474"&gt;Xaliprodene&lt;/ulink&gt; is active in models of progressive motor disability. Experimental autoimmune encephalomyelitis (EAE) clinically stimulates the inflammatory phase of an acute attack of the relapse-remitting form of human multiple sclerosis (MS) in the Lewis rat. This is associated with disruption of the blood-brain barrier and mononuclear cell invasion. Treatment with &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; (1 to 10 mg/kg/day po) starting immediately after the injection of myelin basic protein fragment 68-82 inhibited mononuclear cell invasion of the spinal cord, normalized TNFalpha mRNA expression in spinal cord and maintained the resistance of the brain to penetration by albumin, one the first clinical signs of EAE and probably the key point of acute MS attacks [&lt;ulink linkType="reference" linkID="350048"&gt;350048&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The compound also counteracts the decline in motor function of the progressive motor neuropathy (pnm) mouse, an autosomal recessive mutant in which the homozygotes suffer caudio-cranial degeneration of motor axons and die several weeks after birth. &lt;ulink linkType="Drug" linkID="4474"&gt;Xaliprodene&lt;/ulink&gt; was administered to the mothers of these pups from birth until weaning and the pups then treated until their death. The affected mice treated with &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; had a life span that was 50% longer than that of vehicle-treated mice. The compound also maintained the amplitude of the motor evoked response of the gastrocnemius muscle, reduced the distal motor latency and delayed the occurrence of denervation. Histological studies revealed that at 20 days of age the mean surface areas of the fibers of the sciatic nerve were higher in &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt;-treated mice [&lt;ulink linkType="reference" linkID="291728"&gt;291728&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In the considerably less severe model of age-related memory impairment, assessed by examining acquisition and stabilized performance of an operant-delayed alternation task, &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; increased response accuracy during both phases, but in the stabilized phase the facilitation of response accuracy was observed only in conditions where aged animals showed a deficit compared to young rats. &lt;ulink linkType="Drug" linkID="4474"&gt;Xaliprodene&lt;/ulink&gt; had no effect on performance of young animals at either phase, but interestingly prolonged reaction times in both young and old animals [&lt;ulink linkType="reference" linkID="183260"&gt;183260&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;Amyotrophic lateral sclerosis&lt;/para&gt;&lt;para&gt;The placebo-controlled phase III ALS trials, initiated in May 1997 [&lt;ulink linkType="reference" linkID="346267"&gt;346267&lt;/ulink&gt;], involved the administration of 1 or 2 mg daily doses of &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; for 18 months. One of the trials (EFC 923) also involved administration of 100 mg of &lt;ulink linkType="Drug" linkID="5859"&gt;riluzole&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="23137"&gt;Novartis AG&lt;/ulink&gt;). At this time, filing for ALS was expected in 1999 [&lt;ulink linkType="reference" linkID="270242"&gt;270242&lt;/ulink&gt;]. By December 1998, 2000 patients had been enrolled and the trial results were expected in 2000 [&lt;ulink linkType="reference" linkID="330073"&gt;330073&lt;/ulink&gt;]. By February 2000, both trials had been completed and the results of the trials were being analyzed [&lt;ulink linkType="reference" linkID="359231"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="358849"&gt;358849&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In phase II trials in patients with ALS, &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; has been shown to slow the rate of decline of functional capacities [&lt;ulink linkType="reference" linkID="359231"&gt;359231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a placebo-controlled, phase I/II trial in 32 patients with neurodegenerative diseases, patients exhibited a positive trend in muscle strength and a reduction in the rate of decline of pulmonary function [&lt;ulink linkType="reference" linkID="269672"&gt;269672&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Alzheimer's disease&lt;/subtitle&gt;Phase II studies have demonstrated that &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; slows down the progression of AD and may even help restore cerebral function. At the end of 1997, &lt;ulink linkType="Company" linkID="26495"&gt;Sanofi&lt;/ulink&gt; was negotiating with the regulatory authorities in the design of phase III trials to monitor reversal of AD. At this time, the company expected that recruitment would commence no earlier than the second half of 1998, that the trial would last for about 18 months, and that the drug would be filed in 2001 for this indication [&lt;ulink linkType="reference" linkID="270168"&gt;270168&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="270242"&gt;270242&lt;/ulink&gt;]. However, in February 2000, the compound was still in phase IIb trials for AD [&lt;ulink linkType="reference" linkID="359231"&gt;359231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;The potential use of 5-HT1A receptor agonists and antagonists in diseases such as AD and ALS is the subject of intense debate and activity. In AD, a rationale for the use of such compounds is based, at least in part, on the known interaction in the brain between cholinergic, glutamatergic and serotonergic systems. However, a 5-HT1A receptor antagonist (rather than agonist) would be expected to be the active ligand. The importance of the effects of &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; on NGF function and expression and the role played by the 5-HT1A receptor in its neurotrophic-like properties are unknown, but possibly provide the real basis for the intended use of this substance in neurodegenerative diseases. &lt;/para&gt;&lt;para&gt;It is clear that &lt;ulink linkType="Drug" linkID="4474"&gt;xaliprodene&lt;/ulink&gt; is able to stimulate neurotrophic-like activity in the CNS and has potentially valuable neuroprotective and neuroregenerative properties. The early clinical data are also sugggestive of beneficial therapeutic effects in ALS. A few relatively straightforward preclinical experiments could very quickly determine the relative importance of its affinity for the 5-HT1A receptor and a well-defined mechanism of action would contribute markedly to the acceptance of the compound by the scientific and medical community. As for any chronic disease modifying agent, the clinical trials will be long, complex and expensive and it will be some time before the potential of the compound is fully realised.&lt;/para&gt;&lt;para&gt;Professor David M Jackson, Director, Department of Pharmacology, Preclinical Research and Development, &lt;ulink linkType="Company" linkID="16883"&gt;Astra Arcus AB&lt;/ulink&gt;, Sodertalje, Sweden.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;7 July 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;No data are available on the synthesis of SR-57746A 1-(2-napthylethyl)-4-(3-trifluoromethyl)-1,2,3,6-tetrahydropyridine.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In a variety of in vitro binding studies, SR-57746A has been found to bind with moderate to high affinity at 5-HT1A receptors with Ki values of between 1 to 2 nM.  Little affinity is evident at other 5-HT receptor subtypes, or at other receptors, except sigma opioid receptors [&lt;ulink linkType="reference" linkID="178001"&gt;178001&lt;/ulink&gt;]. The in vivo occupancy of 5-HT1A receptors by injected SR-57746A has been determined, and a dose of 11.1 mg/kg po is able to displace 50 % of the binding of previously injected 3H-8-OH-DPAT.  This occupation of 5-HT1A receptors would appear to be long lasting, with an effect still evident 24 h after systemic administration. Using inhibition of forskolin-stimulated adenylate cyclase in rat hippocampal homogenates suggests that SR-57746A is a full agonist, resembling the reference full agonist 8-OH-DPAT. Consistent with these properties, SR-57746A reduces 5-HT turnover in the brains of rats, via an action on cell body 5-HT1A receptors in the raphe nuclei and, after intravenous injection, inhibits the firing of raphe neurons. These data are all consistent with the properties of a 5-HT1A agonist [&lt;ulink linkType="reference" linkID="178001"&gt;178001&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Also consistent with the biochemical picture of a 5-HT1A agonist are the effects of SR-57746A in various in vivo models. SR-57746A exerts antidepressant-, anti-anxiety- and anti-aggressive-like effects in several animal models, including reducing immobility in the forced swimming test in rats, reducing the time spent in the dark side of the light/dark box (an anti-anxiety test) and reducing aggressive behavior in isolated mice [&lt;ulink linkType="reference" linkID="135344"&gt;135344&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="155242"&gt;155242&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="184473"&gt;184473&lt;/ulink&gt;]. These in vivo effects occurred at doses that should occupy 5-HT1A receptors. This profile is, however, typical of other 5-HT1A agonists such as &lt;ulink linkType="Drug" linkID="3399"&gt;ipsapirone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4838"&gt;flesinoxan&lt;/ulink&gt;. Oddly, SR-57746A is only weakly potent in inducing the so-called "5-HT syndrome" and hypothermia - why this is so is not understood, but partial agonists are generally weaker in some models, although the compound is said to be a full agonist [&lt;ulink linkType="reference" linkID="178001"&gt;178001&lt;/ulink&gt;]. It would be interesting to know if SR-57746A can block the effect of reference full agonists such as 8-OH-DPAT in vivo, a functional way of assessing agonism-antagonism. &lt;/para&gt;&lt;para&gt;5-HT1A ligands modulate cholinergic function both in vivo and in vitro in a variety of preparations. For example, in vitro treatment of primary cultures of fetal rat septal neurons with 8-OH-DPAT, &lt;ulink linkType="Drug" linkID="3399"&gt;ipsapirone&lt;/ulink&gt;, gepirone and &lt;ulink linkType="Drug" linkID="44364"&gt;buspirone&lt;/ulink&gt; increases choline acetyltransferase activity after 6 to 7 days in culture [&lt;ulink linkType="reference" linkID="178007"&gt;178007&lt;/ulink&gt;]. This effect can be prevented by pretreatment with the 5-HT1A antagonist (+)-&lt;ulink linkType="Drug" linkID="4883"&gt;WAY-100135&lt;/ulink&gt;, suggesting that the effect is modulated by 5-HT1A receptors. This interaction may be due to 5-HT1A receptors being expressed on septal neurons in culture. SR-57746A, like other 5-HT1A agonists, exerts neurotrophic effects both in vitro and in vivo. Thus it enhances neuronal survival in primary septal neuroblasts in vitro [&lt;ulink linkType="reference" linkID="188299"&gt;188299&lt;/ulink&gt;], and reverses, after systemic administration, the loss of choline acetyltransferase after lesion of the septal neurons of rats with vincristine [&lt;ulink linkType="reference" linkID="188299"&gt;188299&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Using a sub-chronic administration schedule (multiple doses beginning after the initiation of the ischemic insult), SR-57746A has been shown to reduce the hippocampal damage observed in rats induced by transient four-vessel occlusion, a standard model of ischemia [&lt;ulink linkType="reference" linkID="135343"&gt;135343&lt;/ulink&gt;]. Furthermore, vincristine-induced loss of hippocampal and septal cholinergic neurons (assessed by choline acetyltransferase activity) is reduced. Interestingly, these histological/biochemical neuroprotections are mirrored by reductions in the functional impairments (reduced increase in locomotion and effects on short term social memory, respectively) - the coupling of histological/biochemical measures with functional outcome is welcomed and strengthens the credibility in neurodegeneration studies. In a model of traumatic injury, in which the sciatic nerve of rats is crushed, sub-chronic administration of SR-57746A (begun after the insult) has been reported to accelerate the speed of recovery of sensorimotor function [&lt;ulink linkType="reference" linkID="135343"&gt;135343&lt;/ulink&gt;].  No data is available on the acute effects of SR-57746A in these models, and this would be useful data to have. Some of these models are extremely sensitive to temperature changes, with hypothermia being neuroprotective. 5-HT1A agonists (including SR-57746A) markedly reduce temperature in rodents, and it is unclear whether this may have contributed towards some of the effects observed. On the other hand, tolerance occurs to this effect very rapidly, so that a continuing fall in temperature after several doses of SR-57746A would not be expected. &lt;/para&gt;&lt;para&gt;A daily treatment with SR-57746A (10 mg/kg po) over 21 days has been shown to prevent the deficits in short-term memory induced by the intraseptal infusion of 3 nmol of either beta amyloid (1 - 40) or beta amyloid (25 - 35)  peptide fragments [&lt;ulink linkType="reference" linkID="230918"&gt;230918&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;The only published clinical data are in two abstracts [&lt;ulink linkType="reference" linkID="234168"&gt;234168&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="234169"&gt;234169&lt;/ulink&gt;].  No hard data is given here and it is important to make a considered judgement. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;The potential use of 5-HT1A receptor agonists and antagonists in diseases such as Alzheimer's and amyotrophic lateral sclerosis (ALS), is the subject of intense debate and activity. The use of such ligands in these two very different indications would probably depend upon different mechanisms. In Alzheimer's disease, the hypothetical use of SR-57746A may depend upon the known interaction in the brain between cholinergic and 5-HT systems. However, as already mentioned, an antagonist would be expected to be the active ligand.  The importance of the effects of this substance on NGF function and expression are unknown, but possibly provide the basis for the intended use of this substance in other neurodegenerative diseases,  However, these uses remain hypothetical. While the preclinical data supports in part such a conclusion, the translation of these data to the clinical situation requires caution. The models remain in most cases to be validated, by showing that substances active in preclinical models are also active in the clinic. The testing of SR-57746A in Alzheimer's disease, and its continuing development in ALS will be in effect an important concept test.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate><Source id="1029237" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2007-09-17T00:00:00.000Z</StatusDate><Source id="830785" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate><Source id="1029237" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate><Source id="1029237" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate><Source id="1029237" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate><Source id="1029237" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2007-09-17T00:00:00.000Z</StatusDate><Source id="830785" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="678">Neuropathy</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate><Source id="1029237" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2007-09-17T00:00:00.000Z</StatusDate><Source id="830785" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate><Source id="1029237" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24951">Nippon Sanofi</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2003-02-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2006-02-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2003-02-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2001-07-01T00:00:00.000Z</StatusDate><Source id="416909" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2003-09-02T00:00:00.000Z</StatusDate><Source id="503537" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24951">Nippon Sanofi</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>1999-11-01T00:00:00.000Z</StatusDate><Source id="345341" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2004-08-20T00:00:00.000Z</StatusDate><Source id="555709" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="816526" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="816526" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="678">Neuropathy</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="755722" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="755722" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="755722" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="755722" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1089">Neurotoxicity drug-induced</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="755722" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>1999-06-30T00:00:00.000Z</StatusDate><Source id="328910" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>1999-06-30T00:00:00.000Z</StatusDate><Source id="328910" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate>1997-12-01T00:00:00.000Z</StatusDate><Source id="269672" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>1997-11-24T00:00:00.000Z</StatusDate><Source id="270242" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>1995-06-01T00:00:00.000Z</StatusDate><Source id="176815" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>1995-06-01T00:00:00.000Z</StatusDate><Source id="176815" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26494">Sanofi-Synthelabo</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate>2010-05-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26494">Sanofi-Synthelabo</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2001-01-17T00:00:00.000Z</MileStoneDate><Source id="432268" type="OTHER"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26494">Sanofi-Synthelabo</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2000-11-21T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00011"><Name>5-HT 1a receptor</Name><SwissprotNumbers><Swissprot>P08908</Swissprot><Swissprot>P19327</Swissprot><Swissprot>Q64264</Swissprot><Swissprot>Q6XXX9</Swissprot><Swissprot>Q6XXY0</Swissprot><Swissprot>Q9N296</Swissprot><Swissprot>Q9N297</Swissprot><Swissprot>Q9N298</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1ccc2cc(ccc2c1)CCN3CCC(=CC3)c4cccc(c4)C(F)(F)F</Smiles><Smiles>c1ccc2cc(ccc2c1)CCN3CCC(=CC3)c4cccc(c4)C(F)(F)F.Cl</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1206998" number="WO-09925363" title="Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as Alzheimer dementia."/><PatentFamily id="1492947" number="EP-00101381" title="Anorexic trifluoromethyl phenyl tetrahydropyridines, process for their preparation and pharmaceutical compositions containing them."/><PatentFamily id="1682722" number="WO-09853821" title="Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-beta 1."/><PatentFamily id="1753106" number="WO-09828272" title="Micro-particulate form of a tetrahydropyridin derivative."/><PatentFamily id="177904" number="WO-03020281" title="Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma"/><PatentFamily id="2222449" number="US-20090076048" title="Deuterium-enriched xaliproden"/><PatentFamily id="716652" number="WO-2005046615" title="Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kao Corp" id="17642"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>